FOCL logo

EDAP TMS SA -ADR

FOCLNASDAQ
πŸ† #3733 by market capEarnings Nov 4US Equity
$4.29β–Ό $0.04 (βˆ’0.92%)
Latest quote
πŸ””
Track FOCL
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.9%
7dβ–² 3.1%
14dβ–² 3.1%
30dβ–Ό 5.9%
ytdβ–² 32.8%
1yβ–² 96.8%
🏦Market Cap
$202M
Small Cap
πŸ“ˆRevenue Growth (YoY)
126.0%
High Growth
πŸ“ŠGross Margin
47.6%
Healthy
πŸ’΅FCF Margin
10.3%
Healthy
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$4.25 – $4.29
52-Week Range
$3.97 – $6.40
Volume (shares)
302
Avg Volume (shares)
β€”
Shares Outstanding
47.2M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
β€”
P/S Ratio
2.4x
EPS (TTM)
$-1.04
Dividend Yield
β€”
FOCL logo

EDAP TMS SA -ADR

FOCL
Financial Trends

Financial history unavailable.

StockOtter Β· stockotter.space

About EDAP TMS SA -ADR

EDAP TMS S.A. operates as a holding company, with its subsidiary primarily focused on the innovation, manufacturing, and distribution of advanced, minimally invasive medical devices engineered to address urological conditions. The company's activities are organized into two principal divisions: High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS). The HIFU segment is dedicated to the creation, production, and commercialization of devices that employ HIFU technology for the precise, non-surgical elimination of certain localized tumors. In contrast, the UDS division concentrates on the entire lifecycleβ€”from development and marketing to manufacturing and servicingβ€”of medical instruments used for the minimally invasive diagnosis and treatment of various urological disorders, particularly urinary stones and other related clinical indications. This enterprise was founded on December 3, 1979, and its corporate headquarters are located in Vaulx-en-Velin, France.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100

Analyst Ratings

β“˜
Consensus
Buy
11 analysts
Strong Buy2
Buy6
Hold3
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.